



Oncternal CEO Dr. Jim Breitmeyer Speaks at Cancer Moonshot Satellite Summit

During President Obama's State of the Union Address in January 2016, he asked Vice President Joe Biden to head up an intensive national effort aimed at making "a decade's worth of advances in cancer prevention, diagnosis, and treatment, in five years": the [Cancer Moonshot](#). This mission has brought together cancer patients, caregivers, clinicians, health organizations, advocacy groups, researchers, technologists, and industry leaders in support of the initiative. The landmark Cancer Moonshot Summit was held on June 29, 2016, in Washington, DC and at 10 official satellite summit locations across the U.S. Oncternal's CEO, James Breitmeyer, M.D., Ph.D., was featured as a panelist at the Satellite Summit in the San Diego area.

Additionally, one of the 10 key recommendations emerging from [Cancer Moonshot Blue Ribbon Panel](#) was that research and development efforts targeting fusion oncoproteins could lead to important advances in pediatric cancers (as this [video](#) describes). Oncternal's TK216 targets and inhibits the fusion protein EWS-FLI1 and is now being studied in a Phase 1 clinical trial in patients with Ewing sarcoma, a serious bone cancer affecting children and young adults.